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Background: Percutaneous left ventricular assist devices (LVADs) can replace traditional intra-aortic balloon pumps for cardiac support during 
high-risk percutaneous coronary interventions (PCIs) due to their superior hemodynamic profile and true myocardial protection. The TandemHeart 
(TH) (Cardiac Assist) and Impella 2.5 (Abiomed) differ in catheter size, vascular access, and mechanism of support.
Methods: 40 consecutive patients undergoing elective high-risk PCI underwent percutaneous LVAD placement (20 with TH, 20 with Impella 2.5) at 
a single center. Preclosure technique of the arterial access site was performed using 2 Perclose devices to minimize vascular complications. Patients 
were followed for in-hospital, 30-day, and one-year freedom from major adverse cardiac events (MACE), defined as myocardial infarction, death, or 
stroke.
Results: There was 100% successful implantation of the Impella 2.5 and the TH, with the similar mean age, and the mean ejection fraction (EF) 
was 26.1 ± 6% vs. 38 ± 18%, respectively (p<0.01). Other high-risk features included involvement of the left main coronary artery (5/20 vs. 8/20), 
prior bypass surgery (3/20 vs. 6/20), and use of rotational atherectomy during the procedure (8/20 vs. 17/20). The implantation times, duration 
of cardiac support, and total procedure times were 4 ± 2, 35 ± 23, 50± 27 minutes vs. 32 ± 10, 72 ± 41, 92 ± 12 minutes (p<0.01). There were no 
in-hospital MACE and one death (unknown cause) occurred at 30 days in the TH group. At one year, freedom from MACE was 80% (16/20) with 4 
deaths (1 unknown, 1 non-cardiac) in the Impella 2.5 group vs. 79% (15/19) with an additional 3 deaths in the TH group. Vascular complications 
were minor, comprising of only small hematomas (3 vs. 1), and the length of stay for both groups was 2 ±1 days.
Conclusions: Both the TH and the Impella 2.5 are safe and feasible with no differences in overall freedom from MACE. Patients requiring Impella 
2.5 were higher-risk with significantly lower EF, implantation time, duration of cardiac support, and total procedure times. Hence, the Imeplla 2.5 
device will be preferred over the TH in high-risk PCIs.
